182 related articles for article (PubMed ID: 32850330)
1. HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib.
Zhang X; Lv J; Wu Y; Qin N; Ma L; Li X; Nong J; Zhang H; Zhang Q; Yang X; Shi H; Wang J; Zhang S
Front Oncol; 2020; 10():1162. PubMed ID: 32850330
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report.
Shan J; Ruan J; Tan Y; Yan L; Chen S; Du M; Wang L
Onco Targets Ther; 2020; 13():9849-9856. PubMed ID: 33061462
[TBL] [Abstract][Full Text] [Related]
3. Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review.
Luo Y; Yao B; Huang P; Zhao Y; Chen J
Ann Palliat Med; 2021 Dec; 10(12):12906-12910. PubMed ID: 35016465
[TBL] [Abstract][Full Text] [Related]
4. Specific
Yang G; Xu H; Hu J; Liu R; Hu P; Yang Y; Li W; Hao X; Zhang S; Xu F; Ai X; Li J; Wang Y
Front Pharmacol; 2022; 13():806737. PubMed ID: 35330827
[No Abstract] [Full Text] [Related]
5. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib exhibits promising activity against the rare
Yang G; Liu R; Tang X
Heliyon; 2024 May; 10(9):e30312. PubMed ID: 38707278
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of
Takeda M; Sakai K; Hayashi H; Tanaka K; Tanizaki J; Takahama T; Haratani K; Nishio K; Nakagawa K
Oncotarget; 2018 Apr; 9(30):21132-21140. PubMed ID: 29765525
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
[TBL] [Abstract][Full Text] [Related]
9. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Pillai RN; Behera M; Berry LD; Rossi MR; Kris MG; Johnson BE; Bunn PA; Ramalingam SS; Khuri FR
Cancer; 2017 Nov; 123(21):4099-4105. PubMed ID: 28743157
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation.
Wu Y; Ni J; Chang X; Zhang X; Zhang L
Thorac Cancer; 2020 Jul; 11(7):2051-2055. PubMed ID: 32458584
[TBL] [Abstract][Full Text] [Related]
11. Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials.
Mao S; Yang S; Liu X; Li X; Wang Q; Zhang Y; Chen J; Wang Y; Gao G; Wu F; Jiang T; Zhang J; Yang Y; Lin X; Zhu X; Zhou C; Ren S
Exp Hematol Oncol; 2023 Jun; 12(1):53. PubMed ID: 37296463
[TBL] [Abstract][Full Text] [Related]
12. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
14. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
17. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
[TBL] [Abstract][Full Text] [Related]
18. Clinical characterization of
Liu Z; Wu L; Cao J; Yang Z; Zhou C; Cao L; Wu H; Shen H; Jin M; Zhang Y; Mao X; Xiang J; Ma K; Li B; Zhang T; Hu Y
Onco Targets Ther; 2018; 11():7323-7331. PubMed ID: 30425522
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer; Single-Institution Experience.
Lee SH; Jeong H; Kim DH; Jang SJ; Kim SW; Yoon S; Lee DH
Cancer Res Treat; 2024 Jan; ():. PubMed ID: 38291744
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
